1. Pink Sheet
  2. >>Geography

Teva’s New Global Specialty Medicines Unit To Be Led By Koremans

Brought in from Sanofi in 2012 as president and CEO of Teva Europe, Rob Koremans now will head a new Global Specialty Medicines unit that CEO Jeremy Levin expects to complement Teva’s generics business. Levin spoke of establishing a “single, differentiated Teva presence” in each market through the two units working together.

Following on CEO Jeremy Levin’s strategic presentation to investors last December, Teva Pharmaceutical Industries Ltd. announced April 24 that it is forming a Global Specialty Medicines (GSM) group to complement its generics business and “establish a single, differentiated Teva presence in [each] market.” Rob Koremans, hired from Sanofi in 2012 as president and CEO of Teva Europe, now will serve as president and CEO of the GSM unit.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

More from Geography